The emergence of CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the treatment paradigm for R/R B-cell NHLs. However, challenges persist in accurately evaluating treatment response and detecting early relapse, necessitating the exploration of novel biomarkers. Circulating tumor DNA (ctDNA) via liquid biopsy is a non-invasive tool for monitoring therapy efficacy and predicting treatment outcomes in B-NHL following CAR-T therapy. By overcoming the limitations of conventional imaging modalities, ctDNA assessments offer valuable insights into response dynamics, molecular mechanisms of resistance, and early detection of molecular relapse. Integration of ctDNA monitoring into clinical practice holds promise for personalized therapeutic strategies, guiding the development of novel targeted therapies, and enhancing patient outcomes. However, standardization of assay methodologies and consensus on clinical response metrics are imperative to unlock the full potential of ctDNA in the management of B-NHL. Prospective validation of ctDNA in clinical trials is necessary to establish its role as a complementary decision aid.
CD19靶向嵌合抗原受体T细胞（CAR-T）疗法的出现，彻底改变了复发/难治性B细胞非霍奇金淋巴瘤的治疗模式。然而，在准确评估治疗反应和早期发现复发方面仍存在挑战，这促使人们探索新的生物标志物。通过液体活检检测循环肿瘤DNA是一种非侵入性工具，可用于监测CAR-T治疗后B细胞非霍奇金淋巴瘤的疗效并预测治疗结果。通过克服传统影像学方法的局限性，ctDNA评估为反应动态、耐药分子机制以及分子复发的早期检测提供了宝贵见解。将ctDNA监测整合到临床实践中，有望推动个体化治疗策略的制定，指导新型靶向疗法的开发，并改善患者预后。然而，要充分发挥ctDNA在B细胞非霍奇金淋巴瘤管理中的潜力，必须实现检测方法的标准化和临床反应评估指标的共识。未来需要在临床试验中对ctDNA进行前瞻性验证，以确立其作为辅助决策工具的作用。
肿瘤(癌症)患者之家